Click on image to view larger version.

Figure 1 Odds ratio of angiographic restenosis, target vessel revascularization, and stent thrombosis associated with Cypher and Taxus stents according to a meta-analysis of studies that directly compared the performance of the two drug-eluting stent platforms in clinical trials (4). This meta-analysis suggested a superior performance of the sirolimus-eluting Cypher stent regarding angiographic restenosis and target lesion revascularization; no difference in the rate of stent thrombosis could be detected between the two DES platforms.